Injectable Hydrogel Used for Sustained Delivery of Vaccine

Brief Description

This technology introduces a novel vaccine delivery system using thermosensitive hydrogels for sustained antigen release, aiming to improve immune response durability and breadth.

Full Description

Researchers at UC Irvine have developed a thermosensitive hydrogel combined with nanoparticle-conjugated antigens and adjuvants to create a depot for slow vaccine release. Upon injection at room temperature, the hydrogel gels at body temperature, allowing for a controlled release of the vaccine, which is shown to enhance dendritic cell activation, antigen presentation, and overall immune response.

Suggested uses

• Vaccines for infectious diseases, particularly those with high mutation rates such as influenza and SARS-CoV-2. 
• Immunotherapy for chronic diseases that can benefit from sustained immune activation. 
• Research tools for studying immune response kinetics and mechanisms.

Advantages

• Enhanced immune response compared to conventional vaccine delivery methods. 
• Long-lasting delivery up to 8 weeks, reducing the need for multiple booster shots. 
• Optimal size (approximately 30 nm in diameter) for dendritic cell uptake. 
• More balanced IgG1/IgG2c ratio indicating a balanced Th1/Th2 response. 
• Modular design adaptable to various pathogens, including those prone to antigenic drift like influenza and SARS-CoV-2.

Patent Status

Patent Pending